TN-0053 PPLICATIONS



Effective Sample Preparation and Rapid LC/MS/MS Analysis of a Large Pain Panel Screen using Strata[™]-X-Drug B Solid Phase Extraction (SPE) and Kinetex[®] Phenyl-Hexyl Core-Shell Technology HPLC/UHPLC Columns

Sky Countryman, Shahana Huq, Seyed Sadjadi, and Erica Pike Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA

Using a single Solid Phase Extraction (SPE) method on a specialized sorbent, 41 pain management drugs from several drug classifications were isolated from urine samples and analyzed by LC/ MS/MS in under 5 minutes using a Kinetex Core-Shell Technology HPLC/UHPLC column. The Strata-X-Drug B SPE sorbent was not only able to successfully extract the entire panel of pain management drugs under investigation but it also helped to reduce the amount of time and solvent required for analysis since the sorbent does not require a condition or equilibration step. The Kinetex Core-Shell Technology column further reduced the amount of time required for analysis by separating all 41 compounds in under 5 minutes, without losing sensitivity.

Introduction

Temazepam

According to a study in 2010, an estimated 34 million people were reported to have used pain relievers nonmedically in their lifetime.¹ With the abuse of pain medications on the rise, it is important that contract laboratories and hospitals have a reliable and efficient means to detect the presence of pain medications within patient samples. The ability to screen for a variety of pain medications at once using a single cleanup method and a quick LC/MS/MS method can result in huge time and solvent savings for contract and hospital laboratories who must process hundreds to thousands of samples per week. For this reason, our work had two goals; 1. Develop an SPE method that could extract 41 pain management drugs from urine samples without sacrificing recovery and 2. Develop an LC/MS/MS method that could be run quickly without sacrificing efficiency or resolution of target drugs. The pain management drugs of interest are listed below in Table 1 and are listed by compound classification.

Table 1 Compound Classification of 41 Pain Management Drugs

Benzodiazepines	Opiates (Semi-Synthetic)	Opiates (Synthetic)	Drugs of Abuse	Other
α -Hydroxyalprazolam	6-MAM	EDDP	Amphetamine	Carisoprodol
Alprazolam	Buprenorphine	Fentanyl	Benzoylecgonine	Meprobamate
Clonazepam	Codeine	Meperidine	Methamphetamine	Tramadol
Diazepam	Hydrocodone	Methadone	MDMA	
Flunitrazepam	Hydromorphone	Naltrexone	MDA	
Flurazepam	Morphine	Norfentanyl	MDEA	
Lorazepam	Naloxone	Normeperidine	Phencyclidine	
Midazolam	Norbuprenorphine	Norpropoxyphene		
Nordiazepam	Oxycodone	Propoxyphene		
Oxazepam	Oxymorphone	Sufentanil		

Materials and Methods

Sample Pretreatment

Measure 200 µL urine (calibrator, control) in a 1.5 mL micro centrifuge tube, add 20 µL combined IS (Internal Standard) spiking solution. Vortex 10-15 seconds then add 100 µL 0.1 M Ammonium acetate buffer (pH 4.0) to each tube, mix/vortex another 15 seconds. Add 40 μL β-Glucuronidase solution (100,000 units/mL). Vortex 10-15 seconds.

Incubate for 2 hours in a shaker at 55 °C to complete hydrolysis of the glucuronides.

Add 400 µl of 0.1% Formic acid and vortex for another 60 seconds. Centrifuge the hydrolyzed samples at 21,000 g for 10 minutes (to separate any proteins). Collect supernatant for further cleanup via Solid Phase Extraction (SPE).

Solid Phase Extraction (SPE)

Cartridge: Strata-X-Drug B. 30 mg/3 mL

Part No.: 8B-S128-TBJ Condition: NOT REQUIRED Equilibrate: NOT REQUIRED Load: Pretreated urine sample Wash 1: 1 mL 0.1 % Formic acid in Water Wash 2: 1 ml Methanol/Water (30:70) Dry: 3 to 4 minutes under 10" Hg vacuum

Elute: 2x 0.5 mL 2 % Ammonium hydroxide in Methanol/Acetonitrile (1:1) Dry down: Dry down completely @ 40-45 °C under a stream of nitrogen


Reconstitute: 200 µL 10 mM Ammonium formate/0.1 % Formic acid in Methanol (85:15)

Analysis was performed using an Agilent® 1100 LC system (Agilent Technologies, Palo Alto, CA, USA) coupled with an API 5000™ LC/MS/MS detector (AB SCIEX, Framingham, MA, USA).


¹ National Survey on Drug Use & Health. Substance Abuse and Mental Health Services Administration (SAMHSA). 2010

TN-0053

APPLICATIONS



LC/MS/MS Separation of 41 Pain Management Drugs Using a Kinetex Core-Shell Technology Phenyl-Hexyl HPLC/UHPLC Column



Compound MRM Parameters

Analyte	Q1	Q3
	(m/z)	(m/z)
6-MAM 1	328.1	165.2
6-MAM 2	328.1	211.2
Alprazolam 1	309.1	281.1
Alprazolam 2	309.1	205.2
Amphetamine 1	136.1	91.0
Amphetamine 2	136.1	119.0
Benzoylecgonine 1	290.1	168.1
Benzoylecgonine 2	290.1	105.0
Buprenorphine 1	468.3	396.2
Buprenorphine 2	468.3	414.3
Carisoprodol 1	261.1	176.2
Carisoprodol 2	261.1	97.2
Clonazepam 1	316.1	270.1
Clonazepam 2	316.1	214.0
Codeine 1	300.2	152.1
Codeine 2	300.2	115.1
Diazepam 1	285.0	193.2
Diazepam 2	285.0	154.1
EDDP 1	278.2	234.2
EDDP 2	278.2	186.2
Fentanyl 1	337.3	105.1
Fentanyl 2	337.3	188.2
Flunitrazepam 1	314.1	268.2
Flunitrazepam 2	314.1	239.2
Flurazepam 1	388.2	315.2
Flurazepam 2	388.2	134.1
Hydrocodone 1	300.2	199.0
Hydrocodone 2	300.2	128.0
Hydromorphone 1	286.1	185.1
Hydromorphone 2	286.1	128.0
Hydroxyalprazolam 1	325.1	297.0
Hydroxyalprazolam 2	325.1	216.1
Lorazepam 1	321.0	275.0
Lorazepam 2	321.0	229.0
MDA 1	180.1	133.0
MDA 2	180.1	105.0
MDEA 1	208.2	163.0
MDEA 2	208.2	105.0
MDMA 1	194.1	105.1
MDMA 2	194.1	163.0
Meperidine 1	248.2	220.2
Meperidine 2	248.2	174.2
Meprobamate 1	219.2	158.1
Meprobamate 2	219.2	97.0
Methadone 1	310.0	265.0
Methadone 2	310.0	105.0
Methamphetamine 1	150.1	91.0

TN-0053 APPLICATIONS

Compound MRM Parameters (continued)

Analyte	Q1	Q3
	(m/z)	(m/z)
Midazolam 1	326.1	291.1
Midazolam 2	326.1	249.1
Morphine 1	286.1	152.1
Morphine 2	286.1	165.1
Naloxone 1	328.2	212.0
Naloxone 2	328.2	253.0
Naltrexone 1	342.2	267.1
Naltrexone 2	342.2	212.1
Norbuprenorphine 1	414.3	101.1
Norbuprenorphine 2	414.3	165.2
Nordiazepam 1	271.0	140.0
Nordiazepam 2	271.0	165.1
Norfentanyl 1	233.2	84.1
Norfentanyl 2	233.2	150.1
Normeperidine 1	234.1	160.1
Normeperidine 2	234.1	188.1
Norpropoxyphene 1	308.2	100.1
Norpropoxyphene 2	308.2	143.2
Oxazepam 1	287.0	241.0
Oxazepam 2	287.0	269.1
Oxycodone 1	316.1	241.2
Oxycodone 2	316.1	256.2
Oxymorphone 1	302.1	227.1
Oxymorphone 2	302.1	198.2
PCP 1	244.3	91.1
PCP 2	244.3	159.2
Propoxyphene 1	340.3	266.3
	340.3	91.1
Propoxyphene 2 Sufentanil 1	387.2	238.1
Sufentanii 2	387.2	111.1
Temazepam 1	301.1	255.1
· · · · · · · · · · · · · · · · · · ·	301.1	177.1
Temazepam 2 Tramadol 1	264.1	58.1
Tramadol 2	264.1	42.1
6-MAM-d3	331.1	165.0
Amphetamine-d5	141.1	93.0
Benzoylecgonine-d3	293.1	171.2
Codeine-d6	306.2	152.2
	342.3	
Fentanyl-d5		105.1
Hydrocodone-d6	306.2	202.1
Hydromorphone-d6	292.1	185.1
Meperidine-d4 Methadone-d3	252.2 313.2	224.1 105.1
Methamphetamine-d5	155.2 292.1	92.0
Morphine-d6		152.0
Nordiazepam-d5	276.1	140.0
Normeperidine-d4	238.2	164.2
Norpropoxyphene-d5	313.2	100.1
PCP-d5	249.3	96.1

Transition 1 for each analyte is used as the quantifier transition.

Transition 2 for each analyte is used as the qualifier transition.

Results and Discussion

When developing an analytical method for pain management drugs, two goals were set; 1. Develop an SPE method that could extract 41 pain management drugs from urine samples without sacrificing recovery and 2. Develop an LC/MS/MS method that could be run quickly without sacrificing efficiency or resolution of target drugs. To address our first goal, Strata-X-Drug B SPE was selected as the most appropriate extraction sorbent for several reasons; the sorbent is quality control tested and manufactured for the extraction of drugs of abuse and conditioning and equilibration steps were not required. These benefits provided both time and solvent savings when developing our SPE method.

A majority of our targeted pain management drugs are basic in nature, making the strong cation-exchange function of the Strata-X-Drug B sorbent an ideal chemistry for the extraction of these compounds. In addition to the strong cation-exchange function, the sorbent also has a hydrophobic backbone (due to its polymer base) which further helps to retain our target compounds. For these reasons, our method was able to extract all 41 pain management drugs with an accuracy between 84 to 120 % and precision ranging from 2 to 20 %. Accuracy, precision, and linearity data for several of the 41 target drugs is outlined in **Figures 2** and **3**.

Page 3 of 6

TN-0053

APPLICATIONS

Figure 2 Recovery, Reproducibility, and Linearity of α -Hydroxyalprazolam

Concentration	Precision	Accuracy
(ng/mL)	(n = 3)	
25	2.388	111.4
200	3.384	102.4





Figure 3
Recovery, Reproducibility, and Linearity of Methamphetamine

Concentration	Precision	Accuracy
(ng/mL)	(n = 3)	
125	2.474	113.5
1000	4.489	110.8



After extraction, we began to develop a rapid yet sensitive LC/MS/MS method. A Kinetex $^{\odot}$ 2.6 µm Phenyl-Hexyl Core-Shell Technology HPLC/UHPLC column was chosen because the core-shell particles produce high efficiencies without the added backpressure that is associated with sub-2 µm columns. The Phenyl-Hexyl phase was able to separate compounds based on polarity as well as hydrophobicity, resulting in separation of all 41 compounds in under 5 minutes (**Figure 1**).

Conclusions

Utilizing a single SPE sorbent and protocol, 41 pain management drugs were successfully extracted from urine samples. After cleanup, a rapid and sensitive LC/MS/MS method was performed which resulted in resolution of all 41 pain management drugs in under 5 minutes. The chemistry of the Strata-X-Drug B SPE sorbent was able to target and retain all 41 drugs, providing excellent recoveries for each drug. In addition to high recoveries of all target drugs, the SPE sorbent does not require a conditioning or equilibration step which significantly saves both time and solvent consumption, particularly when applied to a high throughput study. The Kinetex 2.6 µm Core-Shell Technology Phenyl-Hexyl HPLC/UHPLC column further added to our time savings, resulting in a run-time of under 5 minutes. This is due to the unique coreshell design which provides UHPLC results without the increased backpressure.

TN-0053

APPLICATIONS

Ordering Information

Kinetex® Core-Shell HPLC/UHPLC Columns

2.6 µm Analytica	l Columns (mm)			SecurityGuard To ULTRA Cartridges [‡]
Phases	50 x 4.6	100 x 4.6	150 x 4.6	3/pk
Phenyl-Hexyl	00B-4495-E0	00D-4495-E0	00F-4495-E0	AJ0-8774
				for 4.6 mm ID

2.6 µm Minibore	Columns (mm)		SecurityGuard ULTRA Cartridges
Phases	50 x 2.1	100 x 2.1	3/pk
Phenyl-Hexyl	00B-4495-AN	00D-4495-AN	AJ0-8788
			for 2.1 mm ID

^{*}SecurityGuard ULTRA cartridges require holder, Part No. AJ0-9000

Strata™-X-Drug B SPE

Strata	PE	
Sorbent Mass	Part No.	Unit
Tube		
10 mg	8B-S128-AAK	1 mL (100/box)
10 mg	8L-S128-AAK [†]	1 mL (100/box)
30 mg	8B-S128-TAK	1 mL (100/box)
30 mg	8L-S128-TAK [†]	1 mL (100/box)
30 mg	8B-S128-TBJ	3 mL (50/box)
60 mg	8B-S128-UBJ	3 mL (50/box)
60 mg	8B-S128-UCH	6 mL (30/box)
60 mg	8B-S128-UCL	6 mL (200/bag)
Giga™ Tube		
100 mg	8B-S128-EDG	12 mL (20/box)
96-Well Plate		
10 mg	8E-S128-AGB	2 Plates/Box
30 mg	8E-S128-TGB	2 Plates/Box
60 mg	8E-S128-UGB	2 Plates/Box
† Tab-less tube		



Skip the work and instantly run this method using the iMethod™ Kit, a verified method that can be downloaded to your Cliquid® software on your AB SCIEX mass spectrometer. iMethod Kits contain MRM transitions, LC/MS/MS running conditions,

Page 5 of 6

sample preparation recommendations, and all of the consumables you will need to begin running samples.

Visit www.phenomenex.com/iMethod for more information.

Complete iMethod Kit*

Description	Part No.
iMethod Test for the Full Pain Panel V1.2	KH0-9162

^{*} Kit includes Kinetex 2.6 µm Phenyl-Hexyl HPLC/UHPLC column, SecurityGuard ULTRA cartridges and h older, in-line filter, Phenex™ Syringe Filters, Verex™ Vial kit, Sure-Lok™ UHPLC Nut and tightening tool, Sure-Lok Fingertight Nut and wrenches.

Page 4 of 6 For additional technical notes, visit www.phenomenex.com For additional technical notes, visit www.phenomenex.com

TN97881112_W

TN-0053

ICATIONS



Australia

- t: 02-9428-6444
- f: 02-9428-6445 auinfo@phenomenex.com

Austria

- t: 01-319-1301 f: 01-319-1300

anfrage@phenomenex.com

Belaium

- t: +31 (0)30-2418700 f: +31 (0)30-2383749
- beinfo@phenomenex.com

Canada

- t: (800) 543-3681
- (310) 328-7768
- info@phenomenex.com
- Denmark
- t: 4824 8048 f: +45 4810 6265
 - nordicinfo@phenomenex.com

- t: 09 4789 0063
- f: +45 4810 6265
- nordicinfo@phenomenex.com

- t: 01 30 09 21 10
- f: 01 30 09 21 11
 - franceinfo@phenomenex.com

Germany

- t: 06021-58830-0
- f: 06021-58830-11
 - anfrage@phenomenex.com

India

- 040-3012 2400
- f: 040-3012 2411
 - indiainfo@phenomenex.com

- t: 01 247 5405
- f: +44 1625-501796
- eireinfo@phenomenex.com

Italy

- t: 051 6327511
- f: 051 6327555 italiainfo@phenomenex.com

Luxembourg

- t: +31 (0)30-2418700
- +31 (0)30-2383749 nlinfo@phenomenex.com

Mexico

- t: 001-800-844-5226
- f: 001-310-328-7768

tecnicomx@phenomenex.com

- The Netherlands t: 030-2418700
- f: 030-2383749 nlinfo@phenomenex.com

New Zealand

- t: 09-4780951
- f: 09-4780952

nzinfo@phenomenex.com

Norway

- t: 810 02 005
- f: +45 4810 6265 nordicinfo@phenomenex.com

Puerto Rico

- t: (800) 541-HPLC (310) 328-7768
- info@phenomenex.com

Sweden

- t: 08 611 6950
- f: +45 4810 6265 nordicinfo@phenomenex.com

United Kingdom

- t: 01625-501367
- f: 01625-501796
- ukinfo@phenomenex.com

United States

- t: (310) 212-0555
- (310) 328-7768 info@phenomenex.com

Corporate Office USA All other countries:



- t: (310) 212-0555
- (310) 328-7768 info@phenomenex.com

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country, contact Phenomenex UŚA, International Department at international@phenomenex.com



If Phenomenex products in this technical note do not provide at least an equivalent separation as compared to other products of the same phase and comparable dimensions, return the product with comparative data within 45 days for a FULL REFUND.

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at http://www.phenomenex.com/TermsAndConditions

Kintex is a registered trademark of Phenomenx. Strata-X, Phenex, Verex, SecurityGuard, Giga, and Sure-Lok are trademarks of Phenomenex. Agilent is a registered trademark of Agilent Technologies. Cliquid is a registered trademark of AB SCIEX Pte, Ltd. iMethod and API 5000 are trademarks of AB SCIEX Pte, Ltd. AB SCIEX is being used under license.

Strata-X is patented by Phenomenex. U.S. Patent No. 7,119,145.

© 2012 Phenomenex, Inc. All rights reserved.